Benefits
Zero-glycemic natural sweetening
OnoSweet® provides sweetness without glucose or insulin response — monk fruit mogrosides are not absorbed or metabolized by the body and pass through unchanged, while allulose is absorbed but not metabolized (excreted in urine). Both components produce no meaningful glycemic or insulinemic response, making OnoSweet® suitable for diabetics, low-carbohydrate dieters, and anyone managing blood sugar.
Clean taste without artificial sweetener aftertaste
The combination of monk fruit and allulose achieves a taste profile closer to sucrose than either alone. Monk fruit's lingering sweet aftertaste is balanced by allulose's sucrose-like mouthfeel and temporal sweetness profile. This superior taste performance vs. single sweeteners (stevia, erythritol, sucralose) makes OnoSweet® ideal for clean-label products requiring natural, calorie-free sweetening.
Antioxidant and metabolic health properties of mogrosides
Monk fruit mogrosides — beyond their sweetening role — demonstrate antioxidant, anti-inflammatory, and antidiabetic properties in preclinical studies. Mogroside V inhibits advanced glycation end-product (AGE) formation, reduces oxidative stress markers, and shows anti-tumor activity in cell studies. Allulose improves insulin sensitivity and promotes fat oxidation in clinical studies at higher (food-level) intake.
Mechanism of action
Non-metabolizable sweetness and gut microbiome prebiotic effects
Monk fruit mogrosides bind sweet taste receptors (T1R2/T1R3 heterodimers) without enzymatic digestion or intestinal absorption — providing sweetness signal without caloric contribution. Allulose undergoes intestinal absorption but is transported without cellular metabolism and excreted renally. At higher intakes, allulose selectively modulates gut microbiome composition (increasing Akkermansia muciniphila) with potential metabolic benefits beyond its sweetener role.
Clinical trials
Multiple clinical studies and meta-analyses examining allulose effects on glycemic response, insulin sensitivity, and body composition. (Hayashi et al. 2010; or related allulose meta-analyses)
Pooled across allulose RCTs.
Allulose at sweetener replacement doses produced no meaningful glycemic or insulinemic response vs sucrose controls. Modest benefits on postprandial glucose when added to carbohydrate meals. Generally well-tolerated; GI symptoms (gas, diarrhea) at high doses (>0.4 g/kg). FDA recognizes allulose as an 'allowable' sweetener; it's exempt from added sugars labeling per 2019 FDA guidance.